Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis

Utz, Kathrin S.; Hoog, J. M. C.; Wentrup, Andreas; Berg, Sebastian; Lämmer, Alexandra; Jainsch, Britta; Waschbisch, Anne; Lee, Dong Hoon; Linker, Ralf A.; Schenk, Thomas

doi:10.1177/1756285614555335

Cited by 86 publications

(80 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The same result was not observed in the USA 6 , where patients had a strong preference for oral drugs. A German study showed that patients prefer oral drugs over injectable ones if the administration of the pills was once a day 7 .…”

Section: Discussionmentioning

confidence: 99%

Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis

Spessotto

Cavalli

Eboni³

et al. 2016

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

Objective The treatment of multiple sclerosis (MS) with disease-modifying-drugs (DMDs) is evolving and new drugs are reaching the market. Efficacy and safety aspects of the drugs are crucial, but the patients’ satisfaction with the treatment must be taken into consideration. Methods Individual interview with patients with MS regarding their satisfaction and points of view on the treatment with DMDs. Results One hundred and twenty eight patients attending specialized MS Units in five different cities were interviewed. Over 80% of patients were very satisfied with the drugs in use regarding convenience and perceived benefits. The only aspect scoring lesser values was tolerability. Conclusion Parameters for improving treatment in MS must include efficacy, safety, and patient satisfaction with the given DMD.

show abstract

Section: Discussionmentioning

confidence: 99%

Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis

Spessotto

Cavalli

Eboni³

et al. 2016

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

show abstract

“…DCEs have been used previously to study preferences for MS treatments [Johnson et al 2009;Shingler et al 2013;Utz et al 2014;Wicks et al 2015;Wilson et al 2014Wilson et al , 2015. Shingler and colleagues assessed patient preference for features of injection devices and treatment efficacy, showing that while efficacy is of primary importance, device attributes can play an important role in patient preference.…”

Section: Introductionmentioning

confidence: 99%

A discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany

Poulos

Kinter

Yang

et al. 2016

Ther Adv Neurol Disord

View full text Add to dashboard Cite

Objectives: The aim of this study was to assess the relative importance of features of a hypothetical injectable disease-modifying treatment for patients with multiple sclerosis using a discrete-choice experiment. Methods: German residents at least 18 years of age with a self-reported physician diagnosis of multiple sclerosis completed a 25-30 minute online discrete-choice experiment. Patients were asked to choose one of two hypothetical injectable treatments for multiple sclerosis, defined by different levels of six attributes (disability progression, the number of relapses in the next 4 years, injection time, frequency of injections, presence of flu-like symptoms, and presence of injection-site reactions). The data were analyzed using a random-parameters logit model. Results: Of 202 adults who completed the survey, results from 189 were used in the analysis. Approximately 50% of all patients reported a diagnosis of relapsing-remitting multiple sclerosis, and 31% reported secondary progressive multiple sclerosis. Approximately 71% of patients had current or prior experience with injectable multiple sclerosis medication. Approximately 53% had experienced flu-like symptoms caused by their medication, and 47% had experienced mild injection-site reactions. At least one significant difference was seen between levels in all attributes, except injection time. The greatest change in relative importance between levels of an attribute was years until symptoms get worse from 1 to 4 years. The magnitude of this difference was about twice that of relapses in the next 4 years, frequency of injections, and flu-like symptoms. Conclusions: Most attributes examined in this experiment had an influence on patient preference. Patients placed a significant value on improvements in the frequency of dosing and disability progression. Results suggest that changes in injection frequency can be as important as changes in efficacy and safety attributes. Understanding which attributes of injectable therapies influence patient preference could potentially improve outcomes and adherence in patients with multiple sclerosis.

show abstract

“…Однозначно, врач совмест-но с пациентом должен стремиться к сохранению высокой приверженности к терапии, для чего при-меняемый препарат должен быть и эффективен, и хорошо переноситься пациентом. Безусловно, и путь введения препарата оказывает влияние на тера-певтическую комплаентность -применение пер-оральных форм ПИТРС является более привлека-тельным для пациента в отличие от форм инъекци-онных [39].…”

Section: место дмф в современной терапии рсunclassified

Dimethylfumarate in the treatment of relapsing-remitting multiple sclerosis

Popova

Boyko

Orlova³

2016

Z. nevrol. psikhiatr. im. S.S. Korsakova

View full text Add to dashboard Cite

Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis

Abstract: Our results suggest that route of administration and treatment frequency play an important role in the patients' preference for a given DMT.

Cited by 86 publications

References 16 publications

Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis

Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis

A discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany

Dimethylfumarate in the treatment of relapsing-remitting multiple sclerosis

Contact Info

Product

Resources

About